目的 探討康力欣膠囊聯(lián)合甘露聚糖肽治療肝癌的臨床療效。方法 選取2014年2月-2015年7月在玉溪市人民醫(yī)院腫瘤科接受治療的肝癌患者86例,分成對照組(43例)和治療組(43例)。所有患者均給予必要的化療和碘油栓塞治療,1次/周,連續(xù)治療2周。對照組在此基礎(chǔ)上靜脈滴注甘露聚糖肽注射液,10 mg加入250 mL生理鹽水,1次/d。治療組在對照組基礎(chǔ)上口服康力欣膠囊,3粒/次,3次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效,同時比較兩組生存質(zhì)量、免疫功能和血清基質(zhì)金屬蛋白酶水平改善情況。結(jié)果 治療后,對照組客觀緩解率(ORR)為41.86%,臨床獲益率(CBR)為74.42%;治療組ORR為65.12%,CBR為90.70%,兩組ORR、CBR比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,對照組與治療組患者生存質(zhì)量改善率分別為74.42%和93.02%,兩組差異比較具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組CD³⁺、CD⁴⁺和CD⁴⁺/CD⁸⁺上升,差異有統(tǒng)計學(xué)意義(P<0.05);且治療組變化的更顯著(P<0.05)。治療后,兩組血清基質(zhì)金屬蛋白酶-2(MMP-2)和基質(zhì)金屬蛋白酶-9(MMP-9)水平均較同組治療前明顯降低(P<0.05);與對照組相比,治療組降低的更顯著(P<0.05)。結(jié)論 康力欣膠囊聯(lián)合甘露聚糖肽治療肝細(xì)胞癌具有很好的臨床療效,可以提高患者免疫能力及改善生活質(zhì)量,具有一定的臨床應(yīng)用推廣價值。

Epigallocatechin gallate (EGCG) is the main catechin in green tea. A large number of researches have revealed that green tea demonstrates a wide range of positive biological activities against serious chronic diseases, such as cardiovascular disease, neurodegenerative disorders, cancer, metabolic syndrome, and type 2 diabetes. These protective properties can be traced back to the potent antioxidant activities of EGCG. Recent studies have suggested that EGCG may exert its anti-oxidant effects by scavenging free radicals, metal chelation, inhibition of transcription factor activation, and adjusting the oxidation and anti-oxidant enzyme system, etc. This paper summarizes the research progress on anti-oxidative mechanism of EGCG, in order to provide reference for exploiting drugs with same or similar mechanism of EGCG for clinical application.